CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dabigatran etexilate

Last Updated: October 28, 2010
Result type: Reports
Project Number: S0214
Product Line: Reimbursement Review

Generic Name: Dabigatran etexilate

Brand Name: Pradaxa

Manufacturer: Boehringer Ingelheim

Indications: Atrial fibrillation prevention of stroke and systemic embolism

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: June 22, 2011

Recommendation Type: List with clinical criteria and/or conditions